Test de thérapies ciblées dans le cancer à l’aide de l’analyse structurale de l’altération de l’ADN et des Xénogreffes dérivées du patient

Overview

This protocol demonstrates an algorithm for testing the efficacy of targeted therapies based on the genomic makeup of tumors. It includes the identification of structural DNA rearrangements and the engraftment of patient tumors into mice for drug response testing.

Key Study Components

Area of Science

• Oncology
• Genomics
• Pharmacology

Background

• Targeted therapies are selected based on genomic alterations.
• Understanding DNA rearrangements can inform treatment options.
• In vivo models are essential for testing drug efficacy.
• Immunocompromised mice are used for tumor engraftment.

Purpose of Study

• To validate the efficacy of drugs selected through genomic analysis.
• To establish a protocol for in vivo testing of targeted therapies.
• To enhance understanding of tumor responses to specific treatments.

Methods Used

• Whole genome bio-sequencing of human tumor specimens.
• Identification of genomic alterations, including gene rearrangements.
• Selection of potentially druggable changes based on analysis.
• In vivo treatment of tumors in immunocompromised mice.

Main Results

• Successful identification of structural DNA rearrangements.
• Validation of selected drugs in mouse models.
• Demonstration of treatment efficacy based on genomic analysis.
• Insights into tumor behavior in response to targeted therapies.

Conclusions

• The protocol provides a framework for testing targeted therapies.
• Genomic analysis is crucial for selecting effective treatments.
• In vivo models are valuable for understanding drug responses.

Frequently Asked Questions